Salmeterol
- Generic Name
- Salmeterol
- Brand Names
- Advair, Airduo, Airduo Respiclick, Serevent, Serevent Diskus, Wixela
- Drug Type
- Small Molecule
- Chemical Formula
- C25H37NO4
- CAS Number
- 89365-50-4
- Unique Ingredient Identifier
- 2I4BC502BT
- Background
Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD. It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, salbutamol. Salmeterol was first described in the literature in 1988. Salmeterol's structure is similar to salbutamol's with an aralkyloxy-alkyl substitution on the amine.
Salmeterol was granted FDA approval on 4 February 1994.
- Indication
用于哮喘（包括夜间哮喘和运动性哮喘）、喘息性支气管炎和可逆性气道阻塞。
- Associated Conditions
- Asthma, Chronic Obstructive Pulmonary Disease (COPD), Exercise-Induced Bronchospasm
Dupixent Approved for COPD: A New Era in Targeted Therapy
• The FDA has approved Dupixent (dupilumab) for COPD, marking the first targeted therapy addressing the IL-4 and IL-13 pathways linked to type 2 inflammation.
• Clinical trials demonstrated Dupixent reduced moderate-to-severe COPD exacerbations by 30% over 52 weeks, with significant improvements in lung function.
• COPD affects approximately 44 million people in the 7MM, with the market expected to reach USD 16 billion in 2023 and grow at a CAGR of 5% by 2034.
• Emerging therapies like itepekimab, benralizumab, tezepelumab and mepolizumab are in development, poised to further transform the COPD treatment landscape.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath